NSD1 Mutations and Pediatric High-Grade Gliomas: A Comparative Genomic Study in Primary and Recurrent Tumors
暂无分享,去创建一个
S. Rossi | E. Miele | A. Mastronuzzi | F. Giangaspero | I. Giovannoni | F. Buttarelli | M. Gardiman | E. Viscardi | A. Nicolussi | A. Coppa | M. Antonelli | F. Gianno | V. Donofrio | A. d’Amati | S. Minasi | Pietro Lodeserto
[1] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[2] B. Pollo,et al. Correlation Between Immunohistochemistry and Sequencing in H3G34-Mutant Gliomas , 2020, The American journal of surgical pathology.
[3] M. Heuser,et al. Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia , 2020, Cancers.
[4] David T. W. Jones,et al. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. , 2020, Neuro-oncology.
[5] Hsiang-Cheng Chi,et al. DOCK6 promotes chemo- and radioresistance of gastric cancer by modulating WNT/β-catenin signaling and cancer stem cell traits , 2020, Oncogene.
[6] P. Varlet,et al. The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts , 2020, Acta Neuropathologica Communications.
[7] M. Janiszewska. The microcosmos of intratumor heterogeneity: the space-time of cancer evolution , 2019, Oncogene.
[8] Fan Zhang,et al. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway , 2019, Journal of Experimental & Clinical Cancer Research.
[9] Arun K. Ramani,et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.
[10] M. Tartaglia,et al. Role of DNA Methylation Profile in Diagnosing Astroblastoma: A Case Report and Literature Review , 2019, Front. Genet..
[11] Martin Sill,et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience , 2018, Acta Neuropathologica.
[12] Till Acker,et al. DNA methylation-based classification of central nervous system tumours , 2018, Nature.
[13] J. Finlay,et al. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas , 2017, Acta neuropathologica communications.
[14] A. Gentles,et al. NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma , 2017, Scientific Reports.
[15] Kun Mu,et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma , 2017, Cancer cell.
[16] David T. W. Jones,et al. H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers , 2017, Acta Neuropathologica.
[17] David T. W. Jones,et al. Pediatric high-grade glioma: biologically and clinically in need of new thinking , 2016, Neuro-oncology.
[18] Hyung-Goo Kim,et al. Steric Clash in the SET Domain of Histone Methyltransferase NSD1 as a Cause of Sotos Syndrome and Its Genetic Heterogeneity in a Brazilian Cohort , 2016, Genes.
[19] A L Turinsky,et al. NSD1 mutations generate a genome-wide DNA methylation signature , 2015, Nature Communications.
[20] P. Varlet,et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes , 2015, Acta Neuropathologica.
[21] M. Skalej,et al. DOCK6 Mutations Are Responsible for a Distinct Autosomal‐Recessive Variant of Adams–Oliver Syndrome Associated with Brain and Eye Anomalies , 2015, Human mutation.
[22] Yusuke Nakamura,et al. The NSD family of protein methyltransferases in human cancer. , 2015, Epigenomics.
[23] Satoru Miyano,et al. Mutational landscape and clonal architecture in grade II and III gliomas , 2015, Nature Genetics.
[24] Jill S. Barnholtz-Sloan,et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 , 2015, Neuro-oncology.
[25] Volker Hovestadt,et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity , 2015, Acta Neuropathologica.
[26] Chris Jones,et al. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma , 2014, Nature Reviews Cancer.
[27] Peter Canoll,et al. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma , 2014, Proceedings of the National Academy of Sciences.
[28] K. Döhner,et al. Tracing the development of acute myeloid leukemia in CBL syndrome. , 2014, Blood.
[29] Steven J. M. Jones,et al. Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.
[30] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[31] V. Amani,et al. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma , 2014, Acta Neuropathologica.
[32] T. Ogata,et al. Akt and PP2A Reciprocally Regulate the Guanine Nucleotide Exchange Factor Dock6 to Control Axon Growth of Sensory Neurons , 2013, Science Signaling.
[33] V. P. Collins,et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.
[34] Darren Hargrave,et al. Paediatric and adult malignant glioma: close relatives or distant cousins? , 2012, Nature Reviews Clinical Oncology.
[35] S. Scherer,et al. Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.
[36] J. Rice,et al. Role for the nuclear receptor-binding SET domain protein 1 (NSD1) methyltransferase in coordinating lysine 36 methylation at histone 3 with RNA polymerase II function , 2010, Proceedings of the National Academy of Sciences.
[37] F. Giangaspero,et al. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas , 2010, Journal of Neuro-Oncology.